Cell Therapies Pty Ltd
Cell Therapies P/L Secures Additional NCRIS Subsidies for cGMP Compliant Manufacturing | July 2009
Cell Therapies Pty Ltd is pleased to announce that it has recently been awarded new subsidies under the Federal Governments NCRIS scheme.
These new subsidies are directed towards
Maintenance of infrastructure for cGMP compliant processing of human cells at the Center for Blood Cell Therapies (CBCT)
Novel cell tracking by Peter MacCallum researchers and the Peter Mac Diagnostic Imaging department
An additional subsidy for Peter MacCallum’s research involving a phase I study involving an infusion of autologous peripheral blood T lymphocytes transduced with an anti LewisY chimeric receptor gene in patients with LewisY positive Multiple Myeloma, Acute Myeloid Leukaemia or high-risk Myelodysplastic Syndrome.
RISS administers subsidies under the Federal Government's NCRIS scheme. For more information please see
www.risltd.com and
www.ncris.innovation.gov.au
Eligible expenditures offset by subsidy |
CT is in the business of planning and conducting clinical trials
that involve the collection, manipulation and storage of blood cells and human tissue. The services range from laboratory rental through to fully-integrated planning and execution of clinical trials that involve cellular therapeutics manufactured in code of Good Manufacturing Practice (cGMP) and Therapeutic Goods Administration (TGA) licensed facilities.
More about Cell Therapies |
The Centre for Blood Cell Therapy has worked collaboratively with the Therapeutic Goods Administration and others, including the Gene Manipulation Advisory Committee and the Gene Therapy Research Advisory Panel of the National Health and Medical Research Council to ensure on-going compliance with the evolving standards for cell and tissue therapies.
Adhering to international standards |